Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages

被引:126
作者
Zimmerli, S
Edwards, S
Ernst, JD
机构
[1] UNIV CALIF SAN FRANCISCO, DIV INFECT DIS, SAN FRANCISCO, CA 94143 USA
[2] UNIV CALIF SAN FRANCISCO, ROSALIND RUSSELL RES LABS, SAN FRANCISCO, CA 94143 USA
[3] SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA
关键词
D O I
10.1165/ajrcmb.15.6.8969271
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mycobacterium tuberculosis survives and replicates within human macrophages, but the mechanisms whereby tubercle bacilli resist killing are incompletely understood. We tested the general model in which M. tuberculosis evades killing by entering naive macrophages through receptors that are unable to activate cellular microbicidal activities. Complement receptor types 1 (CR1), 3 (CR3), and 4 (CR4) were blocked with monoclonal antibodies, and mannose receptors were blocked with a competitive ligand, mannosylated bovine serum albumin (MESA). Survival and replication of M. tuberculosis (Erdman) were evaluated after the bacteria were phagocytosed in the presence of blocking agents (directing binding to the unblocked receptors). Although there was significant variation in the growth rate of virulent M. tuberculosis in monocyte-derived macrophages from different donors, the intracellular survival and replication of mycobacteria were equivalent regardless of the receptor(s) used fbr binding and phagocytosis. We conclude that the mechanisms whereby M. tuberculosis evades killing by human macrophages are independent of the receptor-mediated route of entry, and operate at one or more steps common to all entry pathways. Blocking complement and mannose receptors in combination did not completely abrogate binding of M. tuberculosis to macrophages. However, we found that two polyanionic scavenger-receptor ligands exhibited a concentration-dependent ability to block binding of M. tuberculosis to macrophages. Moreover, blocking class A scavenger receptors abrogated nearly all binding that persisted after blocking complement and mannose receptors. This indicates that class A scavenger receptors are quantitatively important mediators of M. tuberculosis-macrophage interactions. M. tuberculosis has evolved multiple mechanisms to promote its efficient entry into macrophages. This suggests that passage of the organism through macrophages may be an essential early step in the pathogenesis of tuberculosis.
引用
收藏
页码:760 / 770
页数:11
相关论文
共 37 条
[1]  
ACTON SL, 1994, J BIOL CHEM, V269, P21003
[2]   MEMBRANE TRAFFICKING ALONG THE PHAGOCYTIC PATHWAY [J].
BERON, W ;
ALVAREZDOMINGUEZ, C ;
MAYORGA, L ;
STAHL, PD .
TRENDS IN CELL BIOLOGY, 1995, 5 (03) :100-104
[3]   GENERATION OF SIGNALS ACTIVATING NEUTROPHIL FUNCTIONS BY LEUKOCYTE INTEGRINS - LFA-1 AND GP150/95, BUT NOT CR3, ARE ABLE TO STIMULATE THE RESPIRATORY BURST OF HUMAN NEUTROPHILS [J].
BERTON, G ;
LAUDANNA, C ;
SORIO, C ;
ROSSI, F .
JOURNAL OF CELL BIOLOGY, 1992, 116 (04) :1007-1017
[4]  
CROWLE AJ, 1983, AM REV RESPIR DIS, V128, P673
[5]   RELATIVE PERMISSIVENESS OF MACROPHAGES FROM BLACK AND WHITE PEOPLE FOR VIRULENT TUBERCLE-BACILLI [J].
CROWLE, AJ ;
ELKINS, N .
INFECTION AND IMMUNITY, 1990, 58 (03) :632-638
[6]  
DASILVA RP, 1989, J IMMUNOL, V143, P617
[7]   TRANSFERRIN, IRON, AND SERUM-LIPIDS ENHANCE OR INHIBIT MYCOBACTERIUM-AVIUM REPLICATION IN HUMAN MACROPHAGES [J].
DOUVAS, GS ;
MAY, MH ;
CROWLE, AJ .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (04) :857-864
[8]   HYPERTRIGLYCERIDEMIC SERUM, VERY-LOW-DENSITY LIPOPROTEIN, AND IRON ENHANCE MYCOBACTERIUM-AVIUM REPLICATION IN HUMAN MACROPHAGES [J].
DOUVAS, GS ;
MAY, MH ;
PEARSON, JR ;
LAM, E ;
MILLER, L ;
TSUCHIDA, N .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (05) :1248-1255
[9]   SURFACTANT PROTEIN-A PROMOTES ATTACHMENT OF MYCOBACTERIUM-TUBERCULOSIS TO ALVEOLAR MACROPHAGES DURING INFECTION WITH HUMAN-IMMUNODEFICIENCY-VIRUS [J].
DOWNING, JF ;
PASULA, R ;
WRIGHT, JR ;
TWIGG, HL ;
MARTIN, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (11) :4848-4852
[10]  
DREVETS DA, 1993, J IMMUNOL, V151, P5431